- Conditions
- Lymphoma
- Interventions
- rituximab, carmustine, cytarabine, etoposide, melphalan, ASCT, yttrium Y 90 ibritumomab tiuxetan
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 3,147
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia
- Interventions
- laromustine, temozolomide
- Drug
- Lead sponsor
- Vion Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Durham, North Carolina • Cleveland, Ohio
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Nodal Marginal Zone Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine, Dexamethasone, Epcoritamab, Etoposide Phosphate, Gemcitabine, Ifosfamide, Multigated Acquisition Scan, Oxaliplatin, Rituximab
- Procedure · Drug · Biological
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Relapsed or Refractory Large B-cell Lymphoma
- Interventions
- Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Dexamethasone
- Biological · Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 16
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 12 more
- Conditions
- Recurrence
- Interventions
- Argon Plasma Coagulation, Snare Tip Soft Coagulation
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 384 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 10
- States / cities
- Washington D.C., District of Columbia • Orlando, Florida • Indianapolis, Indiana + 5 more
- Conditions
- Lymphoma, B-Cell
- Interventions
- PS341 (Bortezomib)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 17 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma
- Interventions
- apolizumab
- Biological
- Lead sponsor
- PDL BioPharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Freemont, California
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Gemtuzumab Ozogamicin (GO), Donor Leukocytes
- Drug · Other
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Brain Metastasis
- Interventions
- Standard of Care FDG-PET Imaging
- Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- CD30-positive Lymphoma, CD30-positive Solid Tumor
- Interventions
- Brentuximab Vedotin, Alsertib
- Drug
- Lead sponsor
- Eric Bernicker, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- Capecitabine, Exemestane, Everolimus
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 19
- States / cities
- Los Angeles, California • San Diego, California • Fort Myers, Florida + 15 more
- Conditions
- Cancer
- Interventions
- forodesine hydrochloride
- Drug
- Lead sponsor
- BioCryst Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Promyelocytic Leukemia (M3), Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- selumetinib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds
- Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 85 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Clostridium, Difficile, Fidaxomicin, Vancomycin
- Interventions
- Fidaxomicin, Vancomycin with Taper/Pulse, Vancomycin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
- Conditions
- Major Depressive Disorder, Major Depressive Disorder, Recurrent, Major Depressive Disorder, Remitted
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 13 Years to 21 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult, Hodgkin's Lymphoma, Relapsed, Adult
- Interventions
- MT-601
- Drug
- Lead sponsor
- Marker Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Duarte, California • Aurora, Colorado • Denver, Colorado + 4 more
- Conditions
- Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
- Interventions
- DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360)
- Other · Drug
- Lead sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 6
- States / cities
- Palo Alto, California • Augusta, Georgia • New York, New York + 3 more
- Conditions
- Depression, Pregnancy Related, Antenatal Depression
- Interventions
- Digital Delivery of Mindfulness-Based Cognitive Therapy
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Boulder, Colorado • Boston, Massachusetts
- Conditions
- Colorectal Adenocarcinoma
- Interventions
- Blood draw (venipuncture)
- Other
- Lead sponsor
- Clinical Genomics Pathology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 488 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 12
- States / cities
- Redondo Beach, California • Dover, Delaware • Chicago, Illinois + 9 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
- Interventions
- cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 50 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Recurrent Small Cell Lung Cancer
- Interventions
- imatinib mesylate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Leukemia, Lymphoma
- Interventions
- lumiliximab
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Malignant Glioma
- Interventions
- G207
- Drug
- Lead sponsor
- MediGene
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama